Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature

著录项

• 来源
  《Cancer biology & therapy》 |2020年第12期|共7页
• 作者

  Liu Lei; Liu Yuanyuan; Gong Longbo; Zhang Miao; Wu Wenbin;

  展开▼
• 作者单位

  China Three Gorges Univ Inst Digest Dis Yichang Peoples R China;

  Xuzhou Cent Hosp Dept Surg Oncol 199 Jiefang South Rd Xuzhou Peoples R China;

  Xuzhou Cent Hosp Dept Surg Oncol 199 Jiefang South Rd Xuzhou Peoples R China;

  Xuzhou Cent Hosp Dept Surg Oncol 199 Jiefang South Rd Xuzhou Peoples R China;

  Xuzhou Cent Hosp Dept Surg Oncol 199 Jiefang South Rd Xuzhou Peoples R China;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 肿瘤学;
• 关键词

  camrelizumab (SHR-1210); programmed cell death protein 1 (PD-1); programmed cell death ligand 1 (PD-L1); immune checkpoint inhibitor (ICI); neuroendocrine carcinoma (NEC); apatinib; vascular endothelial growth factor receptor (VEGFR);

  机译：Camrelizumab（ShR-1210）;编程的细胞死亡蛋白1（PD-1）;编程的细胞死亡配体1（PD-L1）;免疫检查点抑制剂（ICI）;神经内分泌癌（NEC）;Apatinib;血管内皮生长因子受体（ VEGFR）;